The Vaxinano's technology, high hope for Covid-19 vaccine
Thursday, April 16th 2020
Nasal vaccination with Vaxinano's nanoparticles against flu virus inhibits virus transmission
Recent publications described that influenza Vaxinano's vaccine administered via a spray by the nasal route allows strong T-cell activation and production of sIgA in the mucosa (Bernasconi V et al., Front. Immunol. 2018). In this new publication (Le MQ et al., Int. J. Pharm. 2020) we demonstrated that Vaxinano's vaccine also inhibits the transmission of the viral infection.
These results are of main importance in the global context of the Covid-19 since the Vaxinano's technology is ready to be transposed to this very infectious coronavirus.
Vaxinano is starting collaborations on the rapid development of an anti-Covid-19 vaccine. New collaborators are welcome to contact us.